Predicting new indications for approved drugs using a proteochemometric method

Journal of Medicinal Chemistry

Volumn 55, Issue 15, 2012, Pages 6832-6848

  Dakshanamurthy, Sivanesan ^a   Issa, Naiem T ^a   Assefnia, Shahin ^a   Seshasayee, Ashwini ^b   Peters, Oakland J ^a   Madhavan, Subha ^a   Uren, Aykut ^a   Brown, Milton L ^a   Byers, Stephen W ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 IMIDAZO[1,2A]PYRIDIN 2 YL)AMINO]BENZENESULFONAMIDE; 4 [2 [4 (2 AMINOETHYL)PIPERAZIN 1 YL]PYRIDIN 4 YL] N (3 CHLORO 4 METHYLPHENYL)PYRIMIDIN 2 AMINE; 5' O [N (ALANYL)SULFAMOYL]ADENOSINE; 5' O [N (SERYL)SULFAOMYL]ADENOSINE; ADENOSINE DERIVATIVE; ALDESULFONE; ATORVASTATIN; BENZENESULFONAMIDE DERIVATIVE; BENZOYLARGINYLALANYLMETHYLKETONE; CADHERIN; CADHERIN 11; CELECOXIB; CLOPIDOGREL; GLUTATHIONE DERIVATIVE; GLUTATHIONE SULFINATE; GLUTATHIONESULFONIC ACID; KETONE DERIVATIVE; LANSOPRAZOLE; MEBENDAZOLE; MONTELUKAST; OLANZAPINE; PENTOSAN POLYSULFATE; PYRIMIDINE DERIVATIVE; QUETIAPINE; RISPERIDONE; ROSUVASTATIN; STAUROSPORINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2; VENLAFAXINE;

ACCURACY; ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CHEMOMETRICS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG APPROVAL; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HISTOGRAM; HOOKWORM; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR DOCKING; PREDICTION; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; PROTEIN FOLDING; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEOCHEMOMETRICS; PROTEOMICS; RHEUMATOID ARTHRITIS; SCORING SYSTEM; VALIDATION PROCESS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIRHEUMATIC AGENTS; CADHERINS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DATABASES, FACTUAL; DRUG DISCOVERY; DRUG REPOSITIONING; DRUGS, INVESTIGATIONAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MEBENDAZOLE; MICE; MODELS, MOLECULAR; NEOVASCULARIZATION, PATHOLOGIC; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEINS; PYRAZOLES; SULFONAMIDES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84864952187     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300576q     Document Type: Article

References (59)

1. Paul, S. M.; Mytelka, D. S.; Dunwiddie, C. T.; Persinger, C. C.; Munos, B. H.; Lindborg, S. R.; Schacht, A. L. How to improve R&D productivity: the pharmaceutical industrys grand challenge Nat. Rev. Drug Discovery 2010, 9, 203-214
2. Lawrence, S. Drug output slows in 2006 Nat. Biotechnol. 2007, 25, 1073
3. Huang, R.; Southall, N.; Wang, Y.; Yasgar, A.; Shinn, P.; Jadhav, A.; Nguyen, D.; Austin, C. The NCGC Pharmaceutical Collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics Sci. Transl. Med. 2011, 3 (80) 80ps16
4. Collins, F. S. Mining for therapeutic gold Nat. Rev. Drug Discovery 2011, 10 (6) 395
5. DiMasi, J. A.; Hansen, R. W.; Grabowski, H. G. The price of innovation: new estimates of drug development costs J. Health Econ. 2003, 22 (2) 151-185
6. Buehler, L. K. Advancing drug discovery-beyond design Pharmagenomics 2004, 4, 24-26
7. Hughes, B. 2007 FDA drug approvals: a year of flux Nat. Rev. Drug Discovery 2008, 7) 107-109
8. Ashburn, T. T.; Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs Nat. Rev. Drug Discovery 2004, 3, 673-683
9. Druker, B. Imatinib as a paradigm of targeted therapies Adv. Cancer Res. 2004, 91, 1-30
10. Young, D.; Bender, A.; Hoyt, J.; McWhinnie, E.; Chirn, G.; Tao, C.; Tallarico, J.; Labow, M.; Jenkins, J.; Mitchison, T.; Feng, Y. Integrating high-content screening and ligand-target prediction to identify mechanism of action Nat. Chem. Biol. 2008, 4, 59-68
11. Wagner, B.; Kitami, T.; Gilbert, T.; Peck, D.; Ramanathan, A.; Schreiber, S.; Golub, T.; Mootha, V. Large-scale chemical dissection of mitochondrial function Nat. Biotechnol. 2008, 26, 343-351
12. Bajorath, J. Computational analysis of ligand relationships within target families Curr. Opin. Chem. Biol. 2008, 12, 352-358
13. Oprea, T.; Tropsha, A.; Faulon, J.; Rintoul, M. Systems chemical biology Nat. Chem. Biol. 2007, 3, 447-450
14. Siegel, M.; Vieth, M. Drugs in other drugs: a new look at drugs as fragments Drug Discovery Today 2007, 12, 71-79
15. Miller, J.; Dunham, S.; Mochalkin, I.; Banotai, C.; Bowman, M.; Buist, S.; Dunkle, B.; Hanna, D.; Harwood, H.; Huband, M.; Karnovsky, A.; Kuhn, M.; Limberakis, C.; Liu, J.; Mehrens, S.; Mueller, W.; Narasimhan, L.; Ogden, A.; Ohren, J.; Prasad, J.; Shelly, J.; Skerlos, L.; Sulavik, M.; Thomas, V.; VanderRoest, S.; Wang, L.; Wang, Z.; Whitton, A.; Zhu, T.; Stover, C. A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 1737-1742
16. Walsh, C. T.; Fischbach, M. A. Repurposing libraries of eukaryotic protein kinase inhibitors for antibiotic discovery Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 1689-1690
17. Keiser, M.; Setola, V.; Irwin, J.; Laggner, C.; Abbas, A.; Hufeisen, S.; Jensen, N.; Kuijer, M.; Matos, R.; Tran, T.; Whaley, R.; Glennon, R.; Hert, J.; Thomas, K.; Edwards, D.; Shoichet, B.; Roth, B. Predicting new molecular targets for known drugs Nature 2009, 462, 175-182
18. Li, Y.; An, J.; Jones, S. A computational approach to finding novel targets for existing drugs PLoS Comput. Biol. 2011, 7, 1-13
19. Cho, Y.; Vermeire, J.; Merkel, J.; Leng, L.; Du, X.; Bucala, R.; Cappello, M.; Lolis, E. Drug repositioning and pharmacophore identification in the discovery of hookworm MIF inhibitors Chem. Biol. 2011, 18, 1089-1101
20. Li, H.; Liu, A.; Zhao, Z.; Xu, Y.; Lin, J.; Jou, D.; Li, C. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3) J. Med. Chem. 2011, 54, 5592-5596
21. Moriaud, F.; Richard, S.; Adcock, S.; Chanas-Martin, L.; Surgand, J.; Jelloul, M.; Delfaud, F. Identify drug repurposing candidates by mining the Protein Data Bank Briefings Bioinf. 2011, 12, 336-340
22. Kinnings, S.; Liu, N; Buchmeier, N; Tonge, P.; Xie, L.; Bourne, P. Drug discovery using chemical systems biology: repositioning the safe medicine comtan to treat multi-drug and extensively drug resistant tuberculosis PLoS Comput. Biol. 2009, 5 (7) e1000423
23. Campillos, M.; Kuhn, M.; Gavin, A.; Jensen, L.; Bork, P. Drug target identification using side-effect similarity Science 2008, 321, 263-266
24. Dudley, J.; Sirota, M.; Shenoy, M.; Pai, R.; Roedder, S.; Chiang, A.; Morgan, A.; Sarwal, M.; Pasricha, P.; Butte, A. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease Sci. Transl. Med. 2011, 3 (96) 96ra76
25. Zhao, X.; Iskar, M.; Zeller, G.; Kuhn, M.; Noort, V.; Bork, P. Prediction of drug combinations by integrating molecular and pharmacological data PLoS Comput. Biol. 2011, 7 (12) e1002323
26. Gottlieb, A.; Stein, G.; Ruppin, E; Sharan, R. PREDICT: a method for inferring novel drug indications with application to personalized medicine Mol. Syst. Biol. 2011, 7, 496
27. Sirota, M.; Dudley, J.; Kim, J.; Chiang, A.; Morgan, A.; Sweet-Cordero, A.; Sage, J.; Butte, A. Discovery and preclinical validation of drug indications using compendia of public gene expression data Sci. Transl. Med. 2011, 3 (96) 96ra77
28. Kolb, P.; Irwin, J. Docking screens: right for the right reasons? Curr. Top. Med. Chem. 2009, 9, 755-770
29. Taylor, R.; Jewsbury, P.; Essex, J. A review of protein-small molecule docking methods J. Comput.-Aided Mol. Des. 2002, 16, 151-166
30. Abagyan, R.; Totrov, M. High-throughput docking for lead generation Curr. Opin. Chem. Biol. 2001, 5 (4) 375-382
31. Warren, G. L.; Andrews, C. W.; Capelli, A.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. A critical assessment of docking programs and scoring functions J. Med. Chem. 2006, 49, 5912-5931
32. Leach, A. R.; Shoichet, B. K.; Peishoff, C. E. Prediction of protein-ligand interactions. Docking and scoring: successes and gaps J. Med. Chem. 2006, 49, 5851-5855
33. Coupez, B.; Lewis, R. A. Docking and scoring: theoretically easy, practically impossible? Curr. Med. Chem. 2006, 13, 2995-3003
34. Kroemer, R. T. Structure-based drug design: docking and scoring Curr. Protein Pept. Sci. 2007, 8 (4) 312-328
35. Kahraman, A.; Morris, R.; Laskowski, R.; Thornton, J. Shape variation in protein binding pockets and their ligands J. Mol. Biol. 2007, 368, 283-301
36. Patel, S. D.; Ciatto, C.; Chen, C. P.; Bahna, F.; Rajebhosale, M.; Arkus, N.; Schieren, I.; Jessell, T. M.; Honig, B.; Price, S. R.; Shapiro, L. Type II cadherin ectodomain structures: implications for classical cadherin specificity Cell 2006, 124 (6) 1255-1268
37. Sc-PDB Home Page. http://cheminfo.u-strasbg.fr:8080/scPDB/2011/db-search/ acceuil.jsp ?uid=3807447192798425088.
38. SYBYL X; Tripos International: St. Louis, MO, U.S.
39. Huang, N.; Shoichet, B.; Irwin, J. Benchmarking sets for molecular docking J. Med. Chem. 2006, 49, 6789-6801
40. Karaman, M.; Herrgard, S.; Treiber, D.; Gallant, P.; Atteridge, C.; Campbell, B.; Chan, K.; Ciceri, P.; Davis, M.; Edeen, P.; Faraoni, R.; Floyd, M.; Hunt, J.; Lockhart, D.; Milanov, Z.; Morrison, M.; Pallares, G.; Patel, H.; Pritchard, S.; Wodicka, L.; Zarrinkar, P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26 (1) 127-132
41. Murzin, A. G.; Brenner, S. E.; Hubbard, T.; Chothia, C. SCOP: a structural classification of proteins database for the investigation of sequences and structures J. Mol. Biol. 1995, 247, 536-540
42. Cho, J. Y.; Katz, D. R.; Chain, B. M. Staurosporine induces rapid homotypic intercellular adhesion of U937 cells via multiple kinase activation Br. J. Pharmacol. 2003, 140, 269-276
43. Martarelli, D.; Pompei, P.; Baldi, C.; Mazzoni, G. Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice Cancer Chemother. Pharmacol. 2008, 61 (5) 809-817
44. Bai, R. Y.; Staedtke, V.; Aprhys, C. M.; Gallia, G. L.; Riggins, G. J. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme Neuro-Oncology 2011, 13 (9) 974-982
45. Montesano, R.; Orci, L.; Vassalli, P. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices J. Cell Biol. 1983, 97, 1648-1652
46. Vailhe, B.; Vittet, D.; Feige, J. In vitro models of vasculogenesis and angiogenesis Lab. Invest. 2001, 81, 439-452
47. Pourgholami, M. H.; Khachigian, L. M.; Fahmy, R. G.; Badar, S.; Wang, L.; Chu, S. W.; Morris, D. L. Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis Biochem. Biophys. Res. Commun. 2010, 397 (4) 729-734
48. Sade, A.; Tuncay, S.; Cimen, I.; Severcan, F.; Banerjee, S. Celecoxib reduces fluidity and decreases metastatic potential of colon cancer cell lines irrespective of COX-2 expression Biosci. Rep. 2012, 32 (1) 35-44
49. Zweers, M. C.; de Boer, T. N.; van Roon, J.; Bijlsma, J. W.; Lafeber, F. P.; Mastbergen, S. C. Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis Arthritis Res. Ther. 2011, 13 (5) 239
50. Cervello, M.; Bachvarov, D.; Cusimano, A.; Sardina, F.; Azzolina, A.; Lampiasi, N.; Giannitrapani, L.; McCubrey, J.; Montalto, G. COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells OMICS 2011, 15 (6) 383-392
51. Sareddy, G. R.; Geeviman, K.; Ramulu, C.; Babu, P. P. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-kappaB pathway J. Neuro-Oncol. 2011, 106 (1) 99-109
52. Schonthal, A. H. Exploiting cyclooxygenase-(in)dependent properties of COX-2 inhibitors for malignant glioma therapy Anti-Cancer Agents Med. Chem. 2010, 10 (6) 450-461
53. Bastos-Pereira, A. L.; Lugarini, D.; Oliveira-Christoff, A.; Avila, T. V.; Teixeira, S.; Pires Ado, R.; Muscará, M. N.; Cadena, S. M.; Donatti, L.; Cristina da Silva de Assis., H.; Acco, A. Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism Cancer Chemother. Pharmacol. 2010, 65 (2) 267-276
54. Tsutsumi, R.; Ito, H.; Hiramitsu, T.; Nishitani, K.; Akiyoshi, M.; Kitaori, T.; Yasuda, T.; Nakamura, T. Celecoxib inhibits production of MMP and NO via down-regulation of NF-kappaB and JNK in a PGE2 independent manner in human articular chondrocytes Rheumatol. Int. 2008, 28 (8) 727-736
55. Miyamoto, K.; Miyake, S.; Mizuno, M.; Oka, N.; Kusunoki, S.; Yamamura, T. Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway Brain 2006, 129 (Part 8) 1984-1992
56. Kusunoki, N.; Yamazaki, R.; Kawai, S. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors Arthritis Rheum. 2002, 46 (12) 3159-3167
57. Tsutsumi, R.; Ito, H.; Hiramitsu, T.; Nishitani, K.; Akiyoshi, M.; Kitaori, T; Yasuda, T.; Nakamura, T. Celecoxib inhibits production of MMP and NO via down-regulation of NF-kappaB and JNK in a PGE2 independent manner in human articular chondrocytes Rheumatol. Int. 2008, 28 (8) 727-736
58. Miyamoto, K.; Miyake, S.; Mizuno, M.; Oka, N.; Kusunoki, S.; Yamamura, T. Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway Brain 2006, 129 (Part 8) 1984-1992
59. Kusunoki, N.; Yamazaki, R.; Kawai, S. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors Arthritis Rheum. 2002, 46 (12) 3159-3167